Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Appears in Networks 2

albuquerque2009 v1.0.0

This file encodes the article Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function by Albuquerque et al, 2009

In-Edges 1

path(MESH:"Smoking Cessation") association a(CHEBI:bupropion) View Subject | View Object

Finally, bupropion (16, 294, 433) and UCI-30002 (514) are examples of synthetic compounds that act as noncompetitive inhibitors of different nAChRs, including those made up of the subunits alpha7, alpha4beta2, or alpha3beta4. Both compounds effectively decrease nicotine self-administration in rats (280, 514). Bupropion is presently approved as an adjunct therapy for smoking cessation. PubMed:19126755

Appears in Networks:
Annotations
Text Location
Review

Out-Edges 7

a(CHEBI:bupropion) decreases act(p(HGNC:CHRNA7)) View Subject | View Object

Finally, bupropion (16, 294, 433) and UCI-30002 (514) are examples of synthetic compounds that act as noncompetitive inhibitors of different nAChRs, including those made up of the subunits alpha7, alpha4beta2, or alpha3beta4. Both compounds effectively decrease nicotine self-administration in rats (280, 514). Bupropion is presently approved as an adjunct therapy for smoking cessation. PubMed:19126755

Appears in Networks:
Annotations
Text Location
Review

a(CHEBI:bupropion) decreases act(p(HBP:"alpha-4 beta-2 nAChR")) View Subject | View Object

Finally, bupropion (16, 294, 433) and UCI-30002 (514) are examples of synthetic compounds that act as noncompetitive inhibitors of different nAChRs, including those made up of the subunits alpha7, alpha4beta2, or alpha3beta4. Both compounds effectively decrease nicotine self-administration in rats (280, 514). Bupropion is presently approved as an adjunct therapy for smoking cessation. PubMed:19126755

Appears in Networks:
Annotations
Text Location
Review

a(CHEBI:bupropion) decreases act(p(HBP:"alpha-3 beta-4 nAChR")) View Subject | View Object

Finally, bupropion (16, 294, 433) and UCI-30002 (514) are examples of synthetic compounds that act as noncompetitive inhibitors of different nAChRs, including those made up of the subunits alpha7, alpha4beta2, or alpha3beta4. Both compounds effectively decrease nicotine self-administration in rats (280, 514). Bupropion is presently approved as an adjunct therapy for smoking cessation. PubMed:19126755

Appears in Networks:
Annotations
Text Location
Review

a(CHEBI:bupropion) association path(MESH:"Smoking Cessation") View Subject | View Object

Finally, bupropion (16, 294, 433) and UCI-30002 (514) are examples of synthetic compounds that act as noncompetitive inhibitors of different nAChRs, including those made up of the subunits alpha7, alpha4beta2, or alpha3beta4. Both compounds effectively decrease nicotine self-administration in rats (280, 514). Bupropion is presently approved as an adjunct therapy for smoking cessation. PubMed:19126755

Appears in Networks:
Annotations
Text Location
Review

a(CHEBI:bupropion) decreases act(a(CHEBI:nicotine)) View Subject | View Object

Other studies have reported that bupropion blocked the acute effects of (-)-nicotine in a number of behavioral assays in mice (e.g., [171, 172]) PubMed:28391535

a(CHEBI:bupropion) increases act(a(MESH:"Central Nervous System")) View Subject | View Object

Bupropion [a.k.a. amfebutamone, (RS)-2-(tert-Butylamino)-1-(3-chlorophenyl)propan1-one, 3-Chloro tert-butylcathinone, 3-Chloro-N-tert-butyl-β-ketoamphetamine; Fig. 4] is a phenylaminoketone or cathinone derivative that is a weak central nervous system (CNS) stimulant PubMed:28391535

a(CHEBI:bupropion) decreases path(MESH:Depression) View Subject | View Object

It is prescribed as medication for the treatment of depression (Wellbutrin®) and/or as an adjunct in smoking cessation therapy (Zyban®). PubMed:28391535

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.